Introduction
Laryngeal carcinoma (LC) is one of the most prevalent malignant tumors of the head and neck squamous cell carcinoma, and more than 90% of cases are pathologically diagnosed as laryngeal squamous cell carcinoma (LSCC). 1, 2 In 2016, there were an estimated 13,430 new diagnosed LSCC cases and about 3,620 LSCC-related deaths in the USA. 3 Despite considerable progress in diagnostic and therapeutic modalities, including surgical resection, radiotherapy and chemotherapy, the clinical outcome of LSCC has not improved greatly due to tumor recurrence and distant metastasis, with the 5-year survival rates of 39%-44% in patients with advanced LC. [4] [5] [6] Therefore, it is imperative to completely understand the molecular mechanisms that underlie the initiation and progression of LSCC.
MicroRNAs (miRNAs) have been considered as potential therapeutic targets for human diseases, including cancer, and have become a novel type of biomarker for cancer diagnosis and treatment. 7 miRNAs are small, single-stranded, noncoding RNAs with 19-22 nucleotides in length that regulate gene expression at the post-transcriptional level through base pairing with the 3′ untranslated region of their target mRNAs. 8 It is widely acknowledged that miRNAs serve significant roles in diverse cellular processes, including cell proliferation, development, cell cycle regulation, apoptosis, cell migration and invasion. 9 Increasing studies have found that numerous miRNAs are abnormally expressed in various types of cancers, including LSCC. 10, 11 These miRNAs have been identified either as oncogenes or as tumor suppressors, which is dependent on the role of their targets. 12 Among these miRNAs, miR-145, located in chromosome 5q32-33, is reported to be downregulated in multiple cancers, including LSCC, and exhibits anti-tumorigenic activity. 13, 14 Curcumin is a polyphenol extracted from the rhizomes of Curcuma longa with extensive biological and pharmacological effects, and has been widely used in People's Republic of China for medicinal purposes for thousands of years. 15 Mounting evidence has addressed the multiple anticancer properties of curcumin, including inhibition of proliferation, invasion, metastasis, angiogenesis and apoptosis induction, suggesting that curcumin has a strong therapeutic potential in multiple cancers through regulating tumor progression. 16, 17 Curcumin could also regulate several signaling pathways related to cell proliferation, apoptosis and progression, such as the phosphoinositol 1,3 kinase (PI3K)/protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) pathway. [18] [19] [20] Additionally, accumulating evidence has indicated that curcumin plays an important role in cancer progression by altering specific miRNA expressions in a variety of cancers. 17, 21, 22 Notably, curcumin was reported to inhibit cell proliferation and promote apoptosis of LC cells through Bcl-2 and PI3K/ Akt, and by upregulating miR-15a. 23 miR-145-5p was able to suppress cell proliferation, invasion and migration and induce apoptosis in melanoma cells by inhibiting the MAPK and PI3K/Akt pathways. 24 However, whether curcumin could regulate the expression of miR-145 via the PI3K/Akt/mTOR pathway in LSCC remains largely unknown.
In the present study, the anticancer effect of curcumin on the development of LSCC was determined. 
Materials and methods

Tissue samples
cell proliferation assay
MTT assay was performed to evaluate cell growth. TU212 and AMC-HN-8 cells were seeded into 96-well plates and incubated for overnight. Subsequently, cells were transfected with miR-145 or miR-NC and incubated for 24 h, 48 h and 72 h. Then, 20 μL MTT (5 mg/mL, Sigma-Aldrich Co.) was added and incubated for 4 h at 37°C. The medium was removed and 150 μL DMSO was added. Following shaking at room temperature for 15 min, the optical density was measured at 490 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Additionally, cell viability was also determined after TU212 and AMC-HN-8 cells were treated with different concentrations of curcumin (0, 5, 10 or 20 μM) for 48 h or treated with anti-miR-145, anti-miR-NC and anti-miR-145 + 20 μM curcumin for 48 h. Cell viability was also assessed after TU212 and AMC-HN-8 cells were transfected with anti-miR-145 or anti-miR-con, followed by treatment with various concentrations of curcumin (0, 20, 40, 60 or 80 μM) for 48 h.
cell cycle analysis
TU212 and AMC-HN-8 cells were collected after treatment with different concentrations of curcumin (0, 5, 10 or 20 μM) for 48 h and fixed with 70% ethanol on ice for 2 h. After washing with ice-cold PBS twice, cells were stained with 0.05 mg/mL propidium iodide (PI; Sigma-Aldrich Co.) and 0.1 mg/mL RNAse (Sigma-Aldrich Co.) for 30 min, and cell cycle distribution was analyzed using a FACSVerse flow cytometer (BD Biosciences, San Jose, CA, USA).
Western blot
TU212 and AMC-HN-8 cells were collected after treatment with anti-miR-145, anti-miR-NC and anti-miR-145 + 20 μM curcumin for 48 h and lysed using a cell lysis buffer (Beyotime, Shanghai, People's Republic of China) containing protease inhibitor phenylmethylsulfonyl fluoride (PMSF) (Beyotime). Cell lysates containing equal amounts of protein were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). After being blocked overnight in 5% skimmed milk in Tris-buffered saline with Tween ® -20, the membranes were incubated overnight at 4°C with specific antibodies against PI3K, Akt, p-Akt, mTOR and p-mTOR (all from Cell Signaling Technology, Beverly, MA, USA). The membranes were washed three times and then incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Abcam, Cambridge, UK) for 1 h at room temperature. The protein bands were detected by the SuperSignal West Pico Chemiluminescent Substrate kit (Pierce Biotechnology, Inc., Rockford, IL, USA).
cell migration and invasion assay
Cell migration and invasion assays were examined using Transwell chamber inserts (Millipore) with or without coated Matrigel (BD Biosciences). TU212 and AMC-HN-8 cells were treated with different concentrations of curcumin (0, 5, 10 or 20 μM) for 48 h or treated with miR-145, miR-NC, anti-miR-145, anti-miR-NC and anti-miR-145 + 20 μM curcumin for 48 h. The treated TU212 and AMC-HN-8 cells (1 × 10 5 /mL) in serum-free medium were seeded into upper chambers of the inserts (Millipore), while 600 μL complete medium containing 10% FBS was added to the lower chambers as a chemoattractant. After incubation for 24 h, non-invading cells were wiped off by cotton swabs and cells on the underside of the inserts were fixed in methanol and stained with 0.1% crystal violet. Cells that invaded to the lower surface were imaged and counted in five randomly selected visual fields using a Nikon TE2000 microscope (Nikon, Tokyo, Japan) with 100× magnification.
Apoptosis analysis by flow cytometry
Cell apoptosis was examined using the Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (BD Pharmingen, San Diego, CA, USA). To measure cell apoptosis, the treated cells were collected, washed with cold PBS twice and re-suspended in 1× binding buffer solution. Then, cells were double stained with Annexin V-FITC and PI for 15 min in the dark. Analyses of cell cycle and cellular apoptosis were 
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statistical analysis
All experimental results were expressed as mean ± standard deviation (SD). GraphPad Prism 5 (GraphPad, San Diego, CA, USA) with two-tailed unpaired Student's t-test was used for statistical analysis. Differences were considered to indicate a statistically significance when P , 0.05.
Results
mir-145 was downregulated in lscc tissues and cells
To assess the role of miR-145 in LSCC, the expression of miR-145 in 32 paired LSCC tissues and adjacent normal tissues was initially detected by qRT-PCR. The results showed that miR-145 was markedly downregulated in 32 paired LSCC tissues when compared with adjacent normal tissues ( Figure 1A Figure 3B ). MTT assay showed that cell viability was effectively decreased in TU212 and AMC-HN-8 cells exposed to 10 or 20 μM curcumin in a dose-dependent manner ( Figure 3C ). Moreover, Transwell migration and invasion assays showed that curcumin administration exerted the similar dose-dependent inhibitory effects on the migration and invasion ability of TU212 and AMC-HN-8 cells ( Figure 3D and E). Additionally, curcumin administration significantly elevated the proportion of cells in the G1 phase and concurrently reduced the proportion of cells in the S phase in a dose-dependent manner in TU212 and AMC-HN-8 cells ( Figure 3F ). In accordance with this, after TU212 and AMC-HN-8 cells were administrated with 10 or 20 μM curcumin for 48 h, the apoptotic rate was significantly increased compared with that in untreated control cells ( Figure 3F ). Figure 4C ). As compared to anti-miR-con group, antimiR-145-introduced TU212 and AMC-HN-8 cells showed remarkably improved migration and invasion abilities, while co-treatment with anti-miR-145 and curcumin significantly attenuated these effects ( Figure 4D and E). Furthermore, flow cytometry analysis demonstrated that miR-145 inhibition conspicuously retarded apoptosis of TU212 and AMC-HN-8 cells compared with control group, while curcumin treatment remarkably recuperated the inhibitory effect of miR-145 inhibition on apoptosis of TU212 and AMC-HN-8 cells ( Figure 4F ). Therefore, it is concluded that curcumin reversed anti-miR-145-induced enhanced effect on the progression of LSCC cells.
curcumin exacerbated mir-145-induced inhibition of the Pi3K/akt/mTOr pathway in lscc cells
To address whether curcumin could regulate the expression of miR-145 via the PI3K/Akt/mTOR pathway in LSCC cells, qRT-PCR and Western blot analysis were conducted to detect the protein levels of PI3K, p-Akt and p-mTOR in TU212 and AMC-HN-8 cells after treatment with miR-145, miR-con, miR-145 + 20 μM curcumin, anti-miR-145, anti-miR-con or anti-miR-145 + 20 μM curcumin. As shown in Figure 5A and B, the protein levels of PI3K, p-Akt and p-mTOR were significantly reduced in miR-145-transfected TU212 and AMC-HN-8 cells but markedly enhanced in anti-miR-145-introduced TU212 and AMC-HN-8 cells. Nevertheless, curcumin treatment dramatically aggravated miR-145-induced inhibition of the PI3K/Akt/mTOR pathway and reversed anti-miR-145-mediated activation of the PI3K/Akt/mTOR pathway in TU212 and AMC-HN-8 cells.
Discussion
LSCC still remains a seriothreat to the life and safety of LSCC patients and thus there is an urgent need to identify effective and safe therapeutic approaches for LSCC. 25 In the present study, it is found that curcumin could significantly inhibit cell proliferation, migration and invasion and promote apoptosis of LSCC cells by upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway.
As a natural active ingredient, extensive biological properties have been identified for curcumin, such as anti-inflammatory, anti-oxidative, anti-infection, anti-liver fibrosis and atherosclerosis. [26] [27] [28] More importantly, curcumin has been found to possess low toxicity but a remarkable anticancer effect on multiple malignancies, such as breast cancer, 29 pancreatic cancer, 30 glioma cancer 31 and gastric cancer, 32 which is in accordance with the results of our study. In the present study, it is demonstrated that curcumin treatment significantly inhibited the progression of LSCC cells by suppressing cell proliferation, migration and invasion and inducing cell cycle arrest and apoptosis, implicating curcumin as a clinically crucial drug for the treatment of LSCC. Consistently, it was previously demonstrated that curcumin could inhibit cell proliferation and promote apoptosis of LC cells. Moreover, a recent study also reported that curcumin could inhibit invasion and vasculogenic mimicry of LSCC in vitro through the inhibition of JAK-2/STAT-3 signaling pathway. 33 Recently, emerging evidence suggests that deregulated miRNAs are frequently demonstrated as biomarkers or therapeutic targets in LSCC, and play a significant role in the pathogenesis of LSCC.
34 miR-145 is well known to be one of the well-characterized tumor suppressor miRNAs whose expression is frequently decreased in distinct types of tumors, such as colorectal cancer 35 breast cancer, 36 ovarian cancer 37 and prostate cancer. 38 It has been also confirmed that miR-145 was downregulated and functioned as a tumor suppressor in LSCC. 14 In line with the previous study, it is verified that miR-145 expression was lower in LSCC tissues and cells, and forced expression of miR-145 inhibited cell proliferation, migration and invasion and promoted apoptosis Additionally, this present study also proved that curcumin reversed anti-miR-145-mediated enhanced effect on the progression of LSCC cells, suggesting that curcumin suppressed the progression of LSCC through upregulation of miR-145, which was similar with the previous study. For example, dendrosomal curcumin was reported to effectively suppress glioblastoma cell proliferation via activation of miR-145. 39 Curcumin was shown to suppress proliferation, in vitro invasion and tumorigenicity of prostate cancer stem cells through ceRNA effect of miR-145 and lncRNA-ROR. 40 However, the probable mechanisms on how curcumin regulate the expression and function of miR-145 are unknown.
The PI3K/AKT/mTOR signaling pathway, a major intracellular signaling pathway, has been extensively studied due to its critical role in cancer progression; it plays indispensable roles in multiple cellular processes, including metabolism, cell growth, survival, migration and differentiation. 41 Overactivation of the PI3K/AKT/mTOR signaling pathway is frequently observed in various types of tumors including LSCC, which are linked to the development and progression of many tumors. 42, 43 Therefore, the PI3K/Akt/mTOR 
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Zhu and Zhu signaling pathway is recognized as the primary pathway for the survival of cancer cells and might be a useful clinical target for the treatment of cancer. 44, 45 It has been shown that curcumin could suppress the activation of the PI3K/Akt/ mTOR signaling pathway in several malignancies, such as gastric cancer 46 and renal cancer. 19 Additionally, curcumin was reported to inhibit cell proliferation and induce apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of the PI3K/ Akt signaling pathway. 47 Furthermore, curcumin was found to inhibit cell proliferation and promote apoptosis of LC cells through inhibiting Bcl-2 expression and the PI3K/ Akt pathway, and by upregulating miR-15a. 23 Similarly, the present study showed that curcumin treatment dramatically aggravated miR-145-induced inhibition of the PI3K/ Akt/mTOR pathway, and reversed anti-miR-145-mediated activation of the PI3K/Akt/mTOR pathway in LSCC cells. Collectively, it is concluded that curcumin suppressed the progression of LSCC through upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway.
Conclusion
The present study focused the effect of curcumin against LSCC cells and demonstrated that curcumin suppressed the progression of LSCC through upregulation of miR-145 and inhibition of the PI3K/Akt/mTOR pathway, providing new insights into the effects and molecular mechanism of curcumin on LSCC. Further in vivo studies are needed to assess the anticancer effects of curcumin on LSCC to confirm the results.
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